A. baumannii is a gram-negative bacillus and a common pathogen of hospital-acquired infections. It causes a variety of infections, including respiratory infections, urinary tract infections, and sepsis. Drug resistance is an important feature and can be resistant to a wide range of antibiotics, including penicillins, fluoroquinolones, and aminoglycosides, making it difficult to treat infections. Poly-β-(1-6)-N-acetylglucosamine (PNAG) is a glycosaminoglycan usually produced by bacteria and plays a key role in the formation and adhesion of bacterial biofilms. Bacteria regulate the synthesis of PNAG through surface-associated genes and release it to the bacterial surface to form an adherent extracellular matrix. These extracellular matrix-forming periplasm not only enhance bacterial adhesion to the environment but also protect bacteria from host immune system attack, thus helping to maintain bacterial structure and increase pathogenicity. Therefore, antimicrobial therapy against PNAG is one of the potential strategies to control bacterial infections in clinical practice.
PNAG has a wide range of promising applications, especially in the biomedical field and antibiotic research. CD BioGlyco has established a Glyco™ Vaccine Development Platform to offer professional Polysaccharide Antigen Production Services to our clients, including A. baumannii PNAG production services. The specific services we offer include the following:
We offer A. baumannii PNAG production services based on the pgaABCD locus encoding A. baumannii PNAG. The enzyme complex encoded by the pgaABCD gene cluster efficiently catalyzes the PNAG synthesis process, resulting in higher yields and rates. It is therefore suitable for the synthesis of large quantities of target products. Moreover, the PNAG synthesized by the pgaABCD gene cluster is highly specific in structure, which ensures that the synthesized PNAG has the desired chemical and functional properties. We will adapt and refine our process to produce PNAG products with different structures or properties to meet your specific research or application requirements.
Fig.1 Process of the PNAG synthesis via the pgaABCD gene cluster. (CD BioGlyco)
CD BioGlyco has an efficient and professional research team to provide A. baumannii PNAG production services to our clients. Our services are not limited to the synthesis of PNAG, we also provide a full range of consulting services to help our clients further explore the use of PNAG in biomedical and glycobiological research. If you are interested in our services, please contact us for more details.
Reference:
